TYP 5.00% 2.1¢ tryptamine therapeutics limited

Where has the chatter gone?, page-3

  1. 285 Posts.
    lightbulb Created with Sketch. 82
    Agreed - I'm certainly waiting to see what deals are realised off the back of the US patent. More broadly, research into exosomes continues to grow at an accelerating pace - which is positive for the pick and shovel play in Exopharm. I'd also note that EX1 is presenting at the Biotech Showcase, which is taking place over 10-12 Jan. Immugene and Radiopharm are also presenting there - will be interesting to see any company release on what will be presented.
 
watchlist Created with Sketch. Add TYP (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.